S&P: Boston Scientific unchanged

Standard & Poor's said it does not believe the recent publicity regarding late stent thrombosis (blood clots) will impact sales of Boston Scientific Corp.'s (BBB+/stable/A-2) Taxus and Liberte drug-eluting stents.

The agency noted that Boston Scientific has met with the FDA to discuss recent findings that indicate a statistically significant difference between late stent thrombosis in drug-eluting versus bare metal stents, adding that the FDA has not taken any action to date.

Bare metal stents, however, are not without risk, given that arteries are more likely to re-clog, S&P said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.